Latest news for Fagron (OTC:ARSUF) Stock

Fagron SA is a pharmaceutical compounding company operating in Belgium. It acts as a supplier of pharmaceutical care to hospitals, pharmacies, clinics, and patients across the world. The company also produces pharmaceutical raw materials, equipment, and supplies that are needed to prepare medication in the pharmacy. Its segments are namely Fagron Europe, Middle East and Africa (EMEA), Fagron North America, and Fagron Latin America. The majority of its revenue comes from Fagron North America.

News

Intraday Update

Markets

Movers

Trading Ideas

AAPL

ADSV

AFYA

ALIAF

ANGPY

AQST

AQUA

ARSUF

ARVN

ASLN

AUDC

AUPH

AXSM

BBDC

BDSI

BLMN

BLXX

BSRTF

CATN

CBFV

AllianzGI Convertible & Income 2024 Target Term Fund Common Shares of Beneficial Interest

CBSH

CFBK

CGOOF

CMXHF

COLL

CSIOY

CSLLY

DALXF

DRNA

EBMT

ECGR

EIFZF

ERRFY

EVFM

FORTY

GLPG

GSEFF

IESC

INCY

INGXF

INSG

JUBPF

KDMN

KNIT

LPLA

MRAAF

MTRAF

NCBDF

NCLTF

Nfj Dividend Interest & Premium Strategy Fund

NTDOY

NTRS

NWPX

NZTCF

OPRT

ORMP

OVID

PCYO

PNFP

PTRDF

QQQX

RHHBF

RLLMF

ROAD

ROST

SAVA

SBGL

SHGDF

SKHHY

Stocks That Hit 52-Week Highs On Monday

Fagron SA

Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.

FDA Earlier Announced Approval Of Bristol-Myers Squibb's Cobenfy With New Mechanism Of Action For Treatment Of Schizophrenia

SEEL

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

NLS PHARMACEUTICS LTD WT PUR COM SER A EXP

NLSPW

NLSP

Offerings

STWD

Starwood Property Trust Prices Private Offering Of $400M Of Its 6.000% Unsecured Senior Notes Due 2030

WIIM

Cassava Sciences shares are trading lower after the SEC charged the company, two former executives for misleading claims about Alzheimer's clinical trial.

SEC announced Cassava Sciences, Inc., its founder and former CEO, Remi Barbier, and its former Senior Vice President of Neuroscience, Lindsay Burns, will pay more than $40 million to settle charges related to misleading statements made in September 2020 about the results of a Phase 2 clinical trial for the company&rsquo;s purported therapeutic for the treatment of Alzheimer&rsquo;s disease.
Without admitting or denying the allegations, Cassava, Barbier, and Burns consented to civil injunctions against future violations and agreed to pay civil penalties of $40 million, $175,000, and $85,000, respectively. Barbier and Burns agreed to be subject to officer-and-director bars of three and five years, respectively. The settlements are subject to court approval.

SEC Charges Cassava Sciences, Two Former Executives For Misleading Claims About Alzheimer's Clinical Trial; Company To Pay Civil Penalty Of $40M

&nbsp;S&amp;P SmallCap 600 constituent SITE Centers Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) is spinning off Curbline Properties in a transaction expected to be completed on October 1.
Cross Country Healthcare is no longer representative of the small-cap market space.&nbsp;

CCRN

CURBw

SITC

Curbline Properties To Be Added To S&P SmallCap 600 Effective Prior To Open Of Trading On October 1, Replacing Cross Country Healthcare

TMDX

TransMedics Group To Replace Ensign Group In S&P SmallCap 600, Effective Prior To Opening Of Trading On October 1

&nbsp;S&amp;P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.&nbsp;

ENSG

Ensign Group Set To Join S&P MidCap 400, Effective Prior To Opening Of Trading On October 1, Replacing Southwestern Energy

As cannabis consumption becomes increasingly common across the U.S., a federal advisory panel is calling for a major shift in how the government handles <a href="https://www.benzinga.com/markets/cannabis/24/09/41049042/with-70-in-favor-could-nebraskas-cannabis-program-unlock-underserved-markets-local-expert-weighs">marijuana policy. </a>
Moving away from the &#8220;Just Say No&#8221; campaigns of the past, Thursday's report from the National Academies of Sciences, Engineering and Medicine advocates for a public health-focused approach, with the Centers for Disease Control and Prevention (CDC) playing a larger role than ever before, PBS News <a href="https://www.pbs.org/newshour/health/u-s-health-authorities-need-to-play-a-larger-role-in-cannabis-policy-report-says">reported.</a>
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/41053493/medical-marijuana-is-still-critical-balancing-act-between-recreational-medicinal-markets">&#8216;Medical Marijuana is Still Critical&#8217;: Balancing Act Between Recreational, Medicinal Markets</a>
<h3 class="wp-block-heading">A Health-Centric Shift In Cannabis Policy</h3>
"We'd like the federal government to step up to provide some leadership in this area," said Dr. Steven Teutsch of the University of Southern California, who chaired the committee behind the report. 
The CDC and the National Institutes of Health (NIH) sponsored the findings, which suggest that the rise of stronger cannabis products coupled with higher rates of daily use necessitate a more robust federal response.
A CDC spokesperson confirmed that the agency is reviewing the report&#8217;s recommendations but stressed that additional funding would be needed to implement them effectively.
<h3 class="wp-block-heading">Escalating Cannabis Potency Raises Public Health Concerns</h3>
One of the report&#8217;s key concerns is the increasing potency of marijuana. "Now you go into the stores, it's hard to find products that are less than 20% THC," noted Beau Kilmer, co-director of the RAND Drug Policy Research Center and a member of the report committee. 
This sharp increase from the roughly 5% THC levels seen 25 years ago has raised alarms over the risks associated with heavy cannabis use, including car accidents and <a href="https://www.benzinga.com/markets/cannabis/23/02/30877367/long-term-marijuana-use-can-lead-to-rare-condition-cannabinoid-hyperemesis-syndrome-say-physic-1">cannabis hyperemesis syndrome</a>, a condition that causes severe vomiting and often requires emergency medical care.
For younger users, the risks extend beyond physical health. According to the report, regular cannabis use among teenagers may interfere with learning and increase the likelihood of developing mood and anxiety disorders. Pregnant women who use cannabis regularly also risk complications for their babies.
<h3 class="wp-block-heading">Cannabis Industry Pushback</h3>
Furthermore, the report notes that cannabis industry lobbying has played a significant role in shaping state policies. In states like Washington and Colorado, efforts to limit THC concentrations or restrict the use of pesticides in cultivation have been met with resistance.
However, Aaron Smith, CEO of the National Cannabis Industry Association, defended the regulated market. "States have protected public health by replacing criminal markets with regulated businesses that are required to test products for contaminants, practice truth in labeling, and most importantly, keep cannabis products out of the hands of minors," said Smith. 
Smith added that legalizing cannabis nationally would allow for more comprehensive federal regulations, ultimately improving public health.
<h3 class="wp-block-heading">Key Recommendations From The Report</h3>
The advisory panel outlined several recommendations aimed at improving cannabis-related public health measures:
<ul>
<li>CDC: Develop and evaluate health campaigns specifically aimed at parents, teens, pregnant women, and older adults. Additionally, the agency should monitor cannabis cultivation, sales, and usage trends, while also establishing best practices for state regulations.</li>
<li>Congress: The report calls for closing a loophole that allows intoxicating hemp-derived products to be sold in states where other cannabis products remain illegal. Congress should also lift restrictions that prevent the Office of National Drug Control Policy from studying the effects of cannabis legalization.</li>
<li>States: Recommendations include requiring cannabis retail staff to undergo training and certification, expunging records for low-level cannabis-related offenses, and adopting U.S. Pharmacopeia quality standards for cannabis products.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/41034042/fbi-report-over-200-000-people-were-arrested-for-cannabis-related-violations-in-2023-how-is-that">FBI Report Over 200,000 People Were Arrested For Cannabis-Related Violations In 2023: How Is That Possible?</a></li>
</ul>

Cannabis

Health Care

Federal Health Agencies Must Take Stronger Role In U.S. Cannabis Policy Shift, New Report Says

Management

TFPM

Triple Flag Precious Metals Appoints Sheldon Vanderkooy As CEO And Director, Succeeding Shaun Usmar Who Departs Effective On September 26, 2024

Michael Garcia, Algoma&#39;s Chief Executive Officer, stated, &quot;Our operations are performing in line with expectations for the fiscal&nbsp;second quarter, despite operating against a backdrop of challenging market conditions for steel demand and pricing.&quot;

Guidance

ASTL

Algoma Steel Expects Q2 Total Steel Shipments Of 510,000 To 520,000 Tons; Says Operations Are Performing In Line With Expectations For The Quarter

BlackBerry Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported second-quarter financial results Thursday after the bell. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/09/ac41057250/blackberry-reports-second-quarter-fiscal-year-2025-results">rundown of the report</a>.
Q2 Earnings: BlackBerry reported second-quarter revenue of $145 million, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $141.42 million. The company reported breakeven second-quarter earnings on an adjusted basis, beating analyst estimates for a loss of 3 cents per share, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
IoT revenue was&nbsp;$55&nbsp;million, up 12% year-over-year.&nbsp;Cybersecurity revenue totaled $87&nbsp;million in the quarter, up 10% year-over-year. Licensing revenue&nbsp;came in at $3&nbsp;million. 
BlackBerry ended the quarter with $265 million in&nbsp;cash, cash equivalents and&nbsp;short-&nbsp;and long-term investments.
&#8220;BlackBerry reached a significant milestone on our path to profitability by recording breakeven adjusted EBITDA and non-GAAP EPS. This result was achieved through a combination of stronger-than-expected, double-digit revenue growth for both IoT and Cybersecurity, as well as tremendous ongoing progress in rationalizing our cost structure. Operating expenses for the quarter were 24% lower than the baseline for the prior year,&#8221; said John Giamatteo, CEO of BlackBerry.
&#8220;QNX delivered strong royalty revenue again this quarter, and there was year-over-year revenue growth for the secure communications products in our Cybersecurity division.&#8221;
See Also: <a href="https://www.benzinga.com/news/24/09/41016947/crowdstrike-executive-struck-by-regret-in-house-hearing-says-company-determined-to-prevent-instances">CrowdStrike Executive Struck By Regret In House Hearing, Says Company Determined To Prevent Instances Like Microsoft Outage From Repeating: &#8216;Deeply Sorry This Happened&#8217;</a>
What&#8217;s Next: BlackBerry expects third-quarter revenue of $146 million to $154 million. BlackBerry sees third-quarter IoT revenue of $56 million to $60 million, cybersecurity revenue of $86 million to $90 million and licensing and other revenue of approximately $4 million. 
The company also guided for breakeven third-quarter earnings, plus or minus one cent per share.
BlackBerry anticipates full-year revenue of $591 million to $616 million. The company anticipates a full-year adjusted earnings loss of 2 cents to 5 cents per share.
Management will hold a conference call to discuss these results at 5:30 p.m. ET.
BB Price Action: <a href="https://www.benzinga.com/quote/BB" target="_blank" rel="noreferrer noopener">BlackBerry shares</a> were up 0.79% in after-hours, trading at $2.56 at the time of publication Thursday, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of BlackBerry.

Earnings

After-Hours Center

BlackBerry Q2 Earnings: Revenue, EPS Beat Estimates Driven By Strength In IoT, Cybersecurity

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual return of 12.86%. Currently, AbbVie has a market capitalization of $338.87 billion. 
Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 10 years ago, it would be worth $3,322.37 today based on a price of $191.90 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727386222_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years

Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) has outperformed the market over the past 10 years by 31.24% on an annualized basis producing an average annual return of 42.65%. Currently, Fair Isaac has a market capitalization of $47.17 billion. 
Buying $100 In FICO: If an investor had bought $100 of FICO stock 10 years ago, it would be worth $3,491.49 today based on a price of $1923.81 for FICO at the time of writing.
<h3>Fair Isaac's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727386217_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FICO

$100 Invested In Fair Isaac 10 Years Ago Would Be Worth This Much Today

Scotiabank Issues C$1.25B, Five-year Sustainability Notes On September 26

The 1-for-15 ratio is within the range approved by the Company&#39;s stockholders at the Special Meeting of Stockholders held on September 19, 2024.

Stock Split

STRM

Streamline Health Plans To Proceed With 1-For-15 Reverse Stock Split Of Its Outstanding Shares Of Common Stock

On September 25, 2024, the board of directors appointed Campbell Becher as President of the Company, effective immediately.
On September 26, 2024, the board of directors appointed Kevin Richardson as Interim Chief Executive Officer and Chief Financial Officer as well as a member of the board of directors.&nbsp;

Qualigen Therapeutics, Inc. - Common Stock

QLGN

Qualigen Therapeutics Says CEO & Chairman Michael Poirier And CFO Christopher Lotz Resign Due To Disagreements With Company Regarding Its Future Direction And Strategic Initiatives

Real Good Food Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGF#NASDAQ">RGF</a>) shares are racing higher in extended trading Thursday after the company announced debt refinancing transactions with PMC Financial Services and Emblem Investment Fund<a href="https://www.benzinga.com/pressreleases/24/09/g41055786/the-real-good-food-company-announces-debt-refinancing-transactions-with-pmc-financial-services-and"> for a $60 million new term loan.</a>
The Details: The company said it will apply $8 million of the proceeds to repay the existing PMC financing and $52 million for transaction fees and general corporate purposes to support the expansion of its manufacturing capabilities and drive several corporate initiatives to position the company for profitable long-term growth. 
Additionally, as part of the agreement, the company issued 19.99% of its outstanding equity to Emblem in the form of Class C Units of its subsidiary, Real Good Food LLC, which are exchangeable into the company&#8217;s common shares.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41036580/expect-healthy-online-spending-this-holiday-season-says-analyst-what-to-know">Expect Healthy Online Spending This Holiday Season, Says Analyst: What To Know</a>
&#8220;We are thrilled to announce these transformational transactions, which provide us with significant liquidity and therefore the capability to make critical investments in our supply chain and strategic initiatives. This will better position our supply chain to meet strong demand for our products and improve service for our customers, which sets the foundation for profitable long-term growth,&#8221; said Tim Zimmer, CEO of Real Good Foods.&nbsp;
Real Good Food Company shares are moving on heavy trading volume following the announcement with more than 7.6 million shares traded in Thursday's session, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.  
RGF Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, the Real Good Food Company shares are up 66.76% after-hours at 62 cents at the time of publication Thursday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41028294/whats-going-on-with-snowflake-stock">What&#8217;s Going On With Snowflake Stock?</a></li>
</ul>
Photo: Gerd Altmann from Pixabay

Penny Stocks

What's Going On With Real Good Food Company Stock?

Fagron

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Fagron

News

Latest news for Fagron (OTC:ARSUF) Stock

Monday, December 02, 2019